Development and Validation of a Nomogram for Predicting the Long-Term Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension

Am J Cardiol. 2022 Jan 15:163:109-116. doi: 10.1016/j.amjcard.2021.09.045. Epub 2021 Nov 10.

Abstract

There remains a lack of prognosis models for patients with chronic thromboembolic pulmonary hypertension (CTEPH). This study aims to develop a nomogram predicting 3-, 5-, and 7-year survival in patients with CTEPH and verify the prognostic model. Patients with CTEPH diagnosed in Fuwai Hospital were enrolled consecutively between May 2013 and May 2019. Among them, 70% were randomly split into a training set and the other 30% as a validation set for external validation. Cox proportional hazards model was used to identify the potential survival-related factors which were candidate variables for the establishment of nomogram and the final model was internally validated by the bootstrap method. A total of 350 patients were included in the final analysis and the median follow-up period of the whole cohort was 51.2 months. Multivariate analysis of Cox proportional hazards regression showed body mass index, mean right atrial pressure, N-terminal pro-brain natriuretic peptide (per 500 ng/ml increase in concentration), presence of anemia, and main treatment choice were the independent risk factors of mortality. The nomogram demonstrated good discrimination with the corrected C-index of 0.82 in the training set, and the C-index of 0.80 (95% CI: 0.70 to 0.91) in the external validation set. The calibration plots also showed a good agreement between predicted and actual survival in both training and validation sets. In conclusion, we developed an easy-to-use nomogram with good apparent performance using 5 readily available variables, which may help physicians to identify CTEPH patients at high risk for poor prognosis and implement medical interventions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Anemia / blood
  • Anemia / complications
  • Angioplasty, Balloon
  • Antihypertensive Agents / therapeutic use
  • Atrial Pressure / physiology*
  • Body Mass Index
  • Chronic Disease
  • Clinical Decision Rules*
  • Endarterectomy
  • Endothelin Receptor Antagonists / therapeutic use
  • Enzyme Activators / therapeutic use
  • Epoprostenol / analogs & derivatives
  • Female
  • Humans
  • Hypertension, Pulmonary / blood
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology*
  • Hypertension, Pulmonary / therapy
  • Male
  • Middle Aged
  • Mortality*
  • Multivariate Analysis
  • Natriuretic Peptide, Brain / blood
  • Nomograms
  • Peptide Fragments / blood
  • Phosphodiesterase 5 Inhibitors / therapeutic use
  • Prognosis
  • Proportional Hazards Models
  • Pulmonary Artery / surgery
  • Pulmonary Embolism / blood
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / physiopathology*
  • Pulmonary Embolism / therapy
  • Pulmonary Wedge Pressure
  • Pyrazoles / therapeutic use
  • Pyrimidines / therapeutic use
  • Reproducibility of Results
  • Survival Rate

Substances

  • Antihypertensive Agents
  • Endothelin Receptor Antagonists
  • Enzyme Activators
  • Peptide Fragments
  • Phosphodiesterase 5 Inhibitors
  • Pyrazoles
  • Pyrimidines
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Epoprostenol
  • riociguat